What are the first‑line mood‑stabilizing medications, their dosing, and monitoring requirements for an adult presenting with an acute manic episode of bipolar disorder?

First-Line Mood Stabilizers for Acute Mania in Bipolar Disorder

For an adult presenting with acute mania, initiate combination therapy with a mood stabilizer (lithium or valproate) plus an atypical antipsychotic (olanzapine, risperidone, or aripiprazole) as the first-line regimen, as this provides superior efficacy compared to monotherapy. 1

---

Medication Selection Algorithm

Combination Therapy (First-Line for Severe Presentations)

• Lithium 900–1800 mg/day (divided doses) PLUS an atypical antipsychotic provides the most robust evidence for acute mania with rapid symptom control 2, 1
• Valproate 750–1500 mg/day (divided doses) PLUS an atypical antipsychotic is equally effective and may be preferred for mixed episodes or rapid cycling 2, 1
• Combination therapy outperforms monotherapy in achieving rapid remission and is considered first-line for severe mania or psychotic features 1, 3

Atypical Antipsychotic Selection

• Olanzapine 10–20 mg/day: Most rapid symptom control, but highest metabolic risk (weight gain, diabetes) 1, 3, 4
• Risperidone 2–6 mg/day: Effective with moderate metabolic risk, but causes prolactin elevation 1, 3
• Aripiprazole 15–30 mg/day: Favorable metabolic profile, lower sedation, preferred when metabolic concerns exist 2, 1, 5
• Quetiapine 400–800 mg/day: Effective but higher metabolic risk than aripiprazole 1, 3

Monotherapy Options (Mild-Moderate Mania Without Psychosis)

• Lithium alone or valproate alone may suffice for less severe presentations 2, 6
• Atypical antipsychotics as monotherapy (olanzapine, risperidone, quetiapine, aripiprazole) are FDA-approved and effective 2, 7, 3

---

Dosing Targets and Monitoring

Lithium

• Target serum level: 0.8–1.2 mEq/L for acute mania 2, 1
• Starting dose: 300 mg three times daily (900 mg/day total) for patients ≥30 kg 2
• Check lithium level after 5 days at steady-state dosing, then twice weekly until stable 1
• Baseline labs (do not delay treatment): CBC, thyroid panel (TSH, free T4), urinalysis, BUN, creatinine, calcium, pregnancy test 2, 1
• Ongoing monitoring (every 3–6 months): Lithium level, renal function, thyroid function, urinalysis 2, 1

Valproate

• Target serum level: 50–100 µg/mL (some sources cite 40–90 µg/mL) 2, 1
• Starting dose: 125 mg twice daily, titrate to therapeutic level; higher initial doses (750–1500 mg/day) for acute mania 2, 1
• Check valproate level after 5–7 days at steady-state dosing 1
• Baseline labs: Liver function tests, CBC with platelets, pregnancy test 2, 1
• Ongoing monitoring (every 3–6 months): Valproate level, liver function, CBC 2, 1

Atypical Antipsychotics

• Baseline metabolic assessment: BMI, waist circumference, blood pressure, fasting glucose, fasting lipid panel 2, 1
• Follow-up monitoring: BMI monthly for 3 months then quarterly; blood pressure, glucose, lipids at 3 months then annually 2, 1

---

Treatment Timeline and Response Assessment

• Clinical effects emerge within 1–2 weeks, but full response requires 4–6 weeks at therapeutic doses 1, 3
• Assess response weekly during the first month using standardized rating scales 1
• Do not conclude treatment failure until completing a full 6–8 week trial at therapeutic drug levels 2, 1
• Verify therapeutic drug levels before declaring monotherapy inadequate 1

---

Adjunctive Treatment for Severe Agitation

• Lorazepam 1–2 mg every 4–6 hours PRN provides superior acute agitation control when added to mood stabilizer plus antipsychotic 2, 1
• The triple combination (mood stabilizer + antipsychotic + benzodiazepine) yields better acute control than any single agent 1
• Limit benzodiazepine use to days-to-weeks to avoid tolerance and dependence 2, 1

---

Maintenance Therapy

• Continue the effective combination for 12–24 months minimum after achieving stabilization 2, 1, 5
• Lithium has the strongest evidence for preventing both manic and depressive recurrences 2, 6, 8
• Do not discontinue prematurely: >90% of noncompliant patients relapse versus 37.5% of compliant patients 2, 1
• Some patients require lifelong treatment, particularly those with multiple severe episodes or rapid cycling 2, 1

---

Critical Pitfalls to Avoid

• Never use antidepressant monotherapy in bipolar disorder—it triggers mania, rapid cycling, and mood destabilization 2, 1, 7
• Avoid typical antipsychotics (haloperidol, fluphenazine) due to high extrapyramidal symptom risk and inferior tolerability 2, 1
• Do not underdose or use insufficient trial duration—must use therapeutic doses for 4–6 weeks before concluding failure 2, 1
• Failure to monitor metabolic side effects with atypical antipsychotics (weight gain, diabetes, dyslipidemia) is a common error 2, 1, 5
• Starting with monotherapy in severe psychotic presentations is suboptimal; combination therapy is first-line 1, 3

---

Psychosocial Interventions (Essential Adjunct)

• Psychoeducation about illness course, treatment options, and medication adherence improves outcomes 2, 1
• Cognitive-behavioral therapy should be offered once acute symptoms stabilize 2, 1
• Family-focused therapy assists with medication supervision and early warning sign identification 2, 1